CI Stock Recent News
CI LATEST HEADLINES
Besides Wall Street's top -and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday.
In the closing of the recent trading day, Cigna (CI) stood at $352.65, denoting a -0.15% change from the preceding trading day.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Cigna Group is one of the few companies that have outperformed the AI-fantasy-driven S&P 500 Index by a wide margin. After a 50% return in less than a year and a new all-time high, it's fair to ask whether it's wise to sell Cigna stock now. In this update, I share my view on Cigna's performance in 2023 and explain why I decided to hold on to my Cigna shares - despite the historically expensive valuation.